TNFRSF8 and mycosis fungoides: In a phase III randomized, multi-center trial, patients with previously treated CD30+ mycosis fungoides (n=97) or pcALCL (n=31) were treated with either brentuximab vedotin (MF n=48; pcALCL n=16) or physician’s choice (MF n=49; pcALCL n=15) of either oral methotrexate or oral bexarotene.